Efficacy and tolerability of bimekizumab within patients with moderate-to-severe plaque psoriasis: learnings from real world evidence

Bimekizumab is the latest biologics approved for the management of moderate-to-severe plaque psoriasis. Its unique mechanism of action simultaneously inhibition of interleukin (IL)17A and IL17F] offers a potentially deeper suppression of cutaneous immune activation compared to selective IL17A inhibition alone. While clinical trials demonstrated excellent results in terms of efficacy and safety, real-world data are mandatory to assess its performance in broader patient populations, including those excluded from trials. This narrative review summarizes findings from real-life studies on bimekizumab in moderate-to-severe plaque psoriasis. Extensive literature research was conducted on the main databases, including PubMed, Embase, Ovid, Scopus, Google Scholar and the Cochrane Library, until April 2025. Bimekizumab has rapidly gained relevance as a highly effective and fast-acting option in psoriasis management, with durable outcomes across heterogeneous patient profiles. The emerging number of real-world evidence reinforces its value in routine practice and supports its positioning as a valuable weapon among the armamentarium of biological therapies.